{
  "id": 12217328,
  "title": "Senior Leerink analyst downgrades Bristol Myers, citing pipeline fears",
  "url": "https://urgent.news/2026/10/05/senior-leerink-analyst-downgrades-bristol-myers-citing-pipeline-fears",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-05T19:40:45.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/senior-leerink-analyst-downgrades-bristol-myers-citing-pipeline-fears/"
  },
  "original_language": "en",
  "account": null,
  "summary": "A Leerink analyst is signaling new bearishness in Bristol Myers Squibb, downgrading his view of the company’s stock because of skepticism about some key upcoming catalysts. David Risinger shifted Bristol Myers' stock from outperform to ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}